Methods

• Cell lines
Human BCR-ABL1 + KU812 and K562 cell lines were obtained from the American Type Culture Collection (ATCC, USA). BCR-ABL1-transduced HL60 cells (HL60-BCRABL) were generated as described previously. 1 All cell lines were cultured in RPMI-1640 media (SigmaAldrich, USA) supplemented with 10% foetal bovine serum (JRH Biosciences, USA), 2 mM L-glutamine (SAFC Biosciences, USA) and 100 U/mL penicillin G/streptomycin (SigmaAldrich) at 37°C with 5% CO 2 in a humidified incubator (Thermo Scientific, AU).
•
Primary samples from CP-CML patients or healthy donors
Primary cells and plasma samples were collected from de novo CP-CML patients enrolled in the TIDEL II study 2 prior to the commencement of imatinib therapy. Peripheral blood was obtained from healthy volunteers. All peripheral blood samples were collected with informed consent in accordance with the Declaration of Helsinki. MNCs were isolated from blood using Lymphoprep (Axis Shield, Norway) density gradient centrifugation. Experiments were performed on cryopreserved cells. Plasma samples were collect using EDTA or heparin as an anticoagulant and stored at -80°C until required.
• Drugs
Imatinib mesylate (STI571) and 14 C-labelled imatinib were kindly provided by Novartis Pharmaceuticals (Switzerland). The potent OCT-1 inhibitor prazosin and PPARγ agonists GW1929, rosiglitazone, pioglitazone, antagonists GW9662 and T0070907 were all purchased from Sigma-Aldrich.
• Lentivirus production and cell transduction
The lentiviral plasmids expressing FLAG-tagged wild-type (WT) PPARγ1 and dominant negative (DN) PPARγ1-L466A/E469A, together with empty vector (EV), were kindly provided by A/Prof Claudine Bonder (Centre for Cancer Biology, Australia). 3 The plasmids were constructed from a previously characterized vector, pLenti4/TO-IRES EGFP. 4 Sequencing analyses verified the integrity of the inserted PPARg1 cDNA.
The packaging cell line Hek293T and lentiviral packaging plasmid (pVSV-G and Pax2) were kindly provided by Prof Andrew Zannettino (University of Adelaide, Australia). HEK293T cells were transfected using Lipofectamine 2000 reagent (Invitrogen Life Technologies, USA) as previously described. 5 Harvested supernatant containing infectious particles filtered through 0.45 µm Nalgene filters (Nalgene Labware, USA) was added to K562 cells at early cell passage.
After 72 hours incubation at 37°C with 5% CO 2 , lentivirus was removed and fresh culture media was added. GFP + cells were isolated using the fluorescence-activated cell sorting (FACS) and selected for subsequent experimentation.
• Imatinib intracellular uptake and retention (IUR) assay and OCT-1 activity (OA)
The IUR assay was performed to measure the intracellular concentration of imatinib achieved and maintained in cells over a 2-hour period, in the presence or absence of OCT-1 inhibition, as previously described. 6, 7 Cell lines or primary MNCs were pre-incubated at 37°C in 5% CO 2 with 40 µM PPARγ ligands for one hour and cell viability prior to the IUR assay was confirmed as greater than 98% by trypan blue exclusion assay. The assays were performed in the presence and absence of 100 µM prazosin, which is a potent inhibitor of OCT-1. The OCT-1 activity is determined by calculating the difference between the IUR in the absence of prazosin and the IUR in the presence of prazosin.
Western blotting analyses and determination of IC50 imatinib values
Western blotting analyses for phosphorylated CrkL (p-CrkL) were performed and IC50 imatinib were determined based on the in vitro reduction in the level of p-CrkL as previously described. 8, 9 Cells were pre-incubated with 40 µM PPARγ ligands for one hour at 37°C in 5% CO 2 prior to exposure to imatinib (ranging from 0 µM to 100 µM).
Whole cell lysates from PPARG-transduced cell extracts were analyzed by western blotting with anti-FLAG M2 antibodies (Sigma-Aldrich, dilution 1:5,000). Anti-PPARγ (H-100, Santa
Cruz Biotechnology, USA, dilution 1:1,000) and alkaline-phosphatase conjugated goat antirabbit IgG secondary antibody (Santa Cruz, dilution 1:2,000) were employed according to the manufacturer's specifications, to determine the protein level of PPARγ. Results were analyzed using ImageLab software 5.0 (Bio-Rad) with GAPDH (Cell Signaling Technology, dilution 1:1,000) as loading control to normalize the PPARg protein.
Cell viability Analyses
Cells were incubated with 10 µM PPARγ ligands for 24 hours at 37°C in 5% CO 2 , prior to an The half-maximal concentration (ED50) that induces cell apoptosis was estimated using nonlinear regression as implemented in the GraphPad™ Prism software program (ver. 7.0a;
GraphPad Software, USA).
• Raw intensities were normalized using the neqc function. Probes were filtered if not detected in any sample based on the detection p-value less than 0.05.
• PPARγ transcriptional activity in MNCs of de-novo CP-CML patients
Nuclear extracts from CP-CML patient diagnostic MNCs were prepared using the Nuclear Extraction Kit (Active Motif, USA) following the manufacturer's protocol. PPARγ transcriptional activity was then measured using the PPARγ Transcription Factor Assay Kit (Active Motif) following the manufacturer's specifications. The absorbance was read on a spectrophotometer (Bio-Tec Instruments, USA) at 450 nm with a reference wavelength of 655 nm.
• Enzyme immunoassays for 15-deoxy-∆12,14-PGJ2 (15d-PGJ2)
The 15d-PGJ2 levels in plasma samples collected from CP-CML patients at diagnosis were analyzed using a 15d-PGJ2 ELISA kit (ENZO Life Sciences, USA) according to the manufacturer's instructions. The absorbance was read on a spectrophotometer at 405 nm with a reference wavelength of 570 nm.
• Statistical Analyses
All statistical analyses were performed using GraphPad Prism version 6.0 (GraphPad Software, USA). Differences were considered to be statistically significant when the p-value was less than 0.05.
